Handelsbanken Fonder AB lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 393,531 shares of the medical research company's stock after acquiring an additional 19,311 shares during the quarter. Thermo Fisher Scientific makes up approximately 0.8% of Handelsbanken Fonder AB's portfolio, making the stock its 18th largest position. Handelsbanken Fonder AB owned about 0.10% of Thermo Fisher Scientific worth $195,821,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after purchasing an additional 196,864 shares during the period. Capital World Investors raised its position in Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after acquiring an additional 104,343 shares during the period. Geode Capital Management LLC boosted its stake in Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after acquiring an additional 197,442 shares during the last quarter. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $3,149,754,000. Finally, Northern Trust Corp raised its holdings in shares of Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the period. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Price Performance
Thermo Fisher Scientific stock traded up $6.00 during mid-day trading on Tuesday, hitting $414.53. 2,573,612 shares of the company traded hands, compared to its average volume of 1,914,596. The stock has a fifty day moving average price of $419.12 and a 200-day moving average price of $494.94. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market cap of $156.48 billion, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the prior year, the firm earned $5.11 earnings per share. The firm's revenue was up .2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.
Insider Activity
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Barclays dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. UBS Group reduced their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Finally, Royal Bank of Canada lowered their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $605.30.
View Our Latest Stock Analysis on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
